ProteqFlu-Te

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Clostridium tetani toxoid / Vcp 2242 virus / Vcp1529 virus / Vcp1533 virus / vCP3011 virus

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QI05AI01

INN (International Name):

equine influenza (live recombinant) and tetanus vaccine

Therapeutic group:

Konji

Therapeutic area:

Immunologicals for equidae, Live viral and inactivated bacterial vaccines, equine influenza virus + clostridium

Therapeutic indications:

Aktivna imunizacija konjev, starih štiri mesece ali več, proti konjski gripi za zmanjšanje kliničnih znakov in izločanja virusa po okužbi ter proti tetanusu za preprečevanje smrtnosti.

Product summary:

Revision: 16

Authorization status:

Pooblaščeni

Authorization date:

2003-03-06

Patient Information leaflet

                                13
B. NAVODILO ZA UPORABO
14
NAVODILO ZA UPORABO
PROTEQFLU-TE SUSPENZIJA ZA INJICIRANJE ZA KONJE.
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
IMETNIKA DOVOLJENJA ZA PROIZVODNJO ZDRAVILA, ODGOVORNEGA ZA
SPROŠČANJE SERIJ V EGP, ČE STA RAZLIČNA
Imetnik dovoljenja za promet z zdravilom :
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
NEMČIJA
Izdelovalec, odgovoren za sproščanje serij:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation,
69800 Saint Priest
FRANCIJA
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
ProteqFlu-Te suspenzija za injiciranje za konje
3.
NAVEDBA ZDRAVILNE UČINKOVIN(E) IN DRUGE(IH) SESTAVIN(E)
En odmerek (1ml) vsebuje:
ZDRAVILNE UČINKOVINE:
Influenza A/eq/Ohio/03 [H
3
N
8
] rekombinantni Canarypox virus (vCP2242) ......... ≥ 5,3 log10 FAID
50
*
Influenza A/eq/Richmond/1/07 rekombinantni Canarypox virus (vCP3011)
.......... ≥ 5,3 log10 FAID
50
*
_Clostridium tetani_
toksoid.
.......................................................................................................
≥ 30 IU**
* vCP vsebnost določena s celokupnim FAID
50
(fluorescenčni test infektivnega odmerka 50 %) in
qPCR razmerjem med vCP.
** titer protiteles proti toksinu po večkratnem cepljenju v serumu
morskih prašičkov po Ph. Eur.
DODATEK:
Karbomer
...........................................................................................................................................
4 mg
4.
INDIKACIJA(E)
Aktivna imunizacija konj, starih 4 mesece ali več proti konjski
influenci za ublažitev kliničnih znakov
in zmanjšanje izločanja virusov po okužbi, ter proti tetanusu za
preprečitev mortalnosti.
Nastop imunosti 14. dan po končanem primarnem cepljenju
Čas trajanja imunosti, ki ga spodbudi predvideni razpored cepljenja:
-
5 mesecev po primarnem cepljenju;
-
Po primarnem cepljenju in poživitvenem cepljenju čez 5 mesecev: 1
leto za influenco konj in 2
leti za tetanus.
5.
KONTRAINDIKACIJE
Jih ni.
15
6.
NEŽELENI UČINKI
•
Na m
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 03-09-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 03-09-2021
Public Assessment Report Public Assessment Report Bulgarian 13-11-2014
Patient Information leaflet Patient Information leaflet Spanish 03-09-2021
Public Assessment Report Public Assessment Report Spanish 13-11-2014
Patient Information leaflet Patient Information leaflet Czech 03-09-2021
Public Assessment Report Public Assessment Report Czech 13-11-2014
Patient Information leaflet Patient Information leaflet Danish 03-09-2021
Public Assessment Report Public Assessment Report Danish 13-11-2014
Patient Information leaflet Patient Information leaflet German 03-09-2021
Public Assessment Report Public Assessment Report German 13-11-2014
Patient Information leaflet Patient Information leaflet Estonian 03-09-2021
Public Assessment Report Public Assessment Report Estonian 13-11-2014
Patient Information leaflet Patient Information leaflet Greek 03-09-2021
Public Assessment Report Public Assessment Report Greek 13-11-2014
Patient Information leaflet Patient Information leaflet English 03-09-2021
Public Assessment Report Public Assessment Report English 13-11-2014
Patient Information leaflet Patient Information leaflet French 03-09-2021
Public Assessment Report Public Assessment Report French 13-11-2014
Patient Information leaflet Patient Information leaflet Italian 03-09-2021
Public Assessment Report Public Assessment Report Italian 13-11-2014
Patient Information leaflet Patient Information leaflet Latvian 03-09-2021
Public Assessment Report Public Assessment Report Latvian 13-11-2014
Patient Information leaflet Patient Information leaflet Lithuanian 03-09-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 03-09-2021
Public Assessment Report Public Assessment Report Lithuanian 13-11-2014
Patient Information leaflet Patient Information leaflet Hungarian 03-09-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 03-09-2021
Public Assessment Report Public Assessment Report Hungarian 13-11-2014
Patient Information leaflet Patient Information leaflet Maltese 03-09-2021
Public Assessment Report Public Assessment Report Maltese 13-11-2014
Patient Information leaflet Patient Information leaflet Dutch 03-09-2021
Public Assessment Report Public Assessment Report Dutch 13-11-2014
Patient Information leaflet Patient Information leaflet Polish 03-09-2021
Public Assessment Report Public Assessment Report Polish 13-11-2014
Patient Information leaflet Patient Information leaflet Portuguese 03-09-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 03-09-2021
Public Assessment Report Public Assessment Report Portuguese 13-11-2014
Patient Information leaflet Patient Information leaflet Romanian 03-09-2021
Public Assessment Report Public Assessment Report Romanian 13-11-2014
Patient Information leaflet Patient Information leaflet Slovak 03-09-2021
Public Assessment Report Public Assessment Report Slovak 13-11-2014
Patient Information leaflet Patient Information leaflet Finnish 03-09-2021
Public Assessment Report Public Assessment Report Finnish 13-11-2014
Patient Information leaflet Patient Information leaflet Swedish 03-09-2021
Public Assessment Report Public Assessment Report Swedish 13-11-2014
Patient Information leaflet Patient Information leaflet Norwegian 03-09-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 03-09-2021
Patient Information leaflet Patient Information leaflet Icelandic 03-09-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 03-09-2021
Patient Information leaflet Patient Information leaflet Croatian 03-09-2021
Public Assessment Report Public Assessment Report Croatian 13-11-2014

View documents history